Jonathan Aschoff
Stock Analyst at Roth Capital
(0.49)
# 4,142
Out of 5,182 analysts
39
Total ratings
24.49%
Success rate
-35.05%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics | Maintains: Buy | $57 → $55 | $24.97 | +120.26% | 2 | Feb 26, 2026 | |
| GTBP GT Biopharma | Initiates: Buy | $11 | $0.28 | +3,788.30% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $9.90 | +112.12% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $199,800 → $106,560 | $4.91 | +2,172,377.06% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $0.22 | +7,975.37% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $714 | $1.11 | +64,224.32% | 2 | Aug 13, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $500 | $1.10 | +45,354.55% | 1 | Jul 16, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $1,000 | $2.56 | +38,962.50% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $600 → $840 | $2.56 | +32,712.50% | 4 | Mar 28, 2024 | |
| HSDT Solana Company | Maintains: Buy | $3,750 → $18,000 | $2.08 | +865,284.62% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $14.60 | +105.48% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $5.85 | +3,318.80% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $8.60 | +62.79% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28,800 → $86,400 | $1.16 | +7,448,175.86% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $1.66 | +381.93% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $2.23 | +4,384.30% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $1.12 | +35,614.29% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $7.65 | +396.73% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $1.15 | +8,247.83% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $1.40 | +828.57% | 1 | Dec 19, 2019 |
Pelthos Therapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $57 → $55
Current: $24.97
Upside: +120.26%
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $0.28
Upside: +3,788.30%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $9.90
Upside: +112.12%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $199,800 → $106,560
Current: $4.91
Upside: +2,172,377.06%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $0.22
Upside: +7,975.37%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $714
Current: $1.11
Upside: +64,224.32%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $500
Current: $1.10
Upside: +45,354.55%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $1,000
Current: $2.56
Upside: +38,962.50%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $600 → $840
Current: $2.56
Upside: +32,712.50%
Solana Company
Mar 5, 2024
Maintains: Buy
Price Target: $3,750 → $18,000
Current: $2.08
Upside: +865,284.62%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $14.60
Upside: +105.48%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $5.85
Upside: +3,318.80%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $8.60
Upside: +62.79%
Feb 14, 2023
Maintains: Buy
Price Target: $28,800 → $86,400
Current: $1.16
Upside: +7,448,175.86%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $1.66
Upside: +381.93%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $2.23
Upside: +4,384.30%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $1.12
Upside: +35,614.29%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $7.65
Upside: +396.73%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $1.15
Upside: +8,247.83%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $1.40
Upside: +828.57%